Eli Lilly and Insilico Medicine Announce $2.75 Billion Partnership for AI-Driven Drug Development

Eli Lilly Partners with Insilico Medicine for $2.75 Billion AI-Powered Deal

Eli Lilly, a leading pharmaceutical company, has entered into a $2.75 billion agreement with Insilico Medicine, a Hong Kong-listed AI-driven drug developer, to leverage artificial intelligence (AI) for global drug development.

Under the agreement, Insilico Medicine will receive $115 million upfront, with additional payments tied to regulatory approvals and commercial milestones, as well as royalties on future sales. Eli Lilly will obtain an exclusive license to develop, manufacture, and commercialize Insilico Medicine's preclinical oral drug candidates in selected disease areas.

Insilico Medicine has developed at least 28 drugs using generative AI tools, with roughly half of them already at a clinical stage. The company's shares have surged over 50% year-to-date following its public listing in Hong Kong in December last year.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

The partnership between Eli Lilly and Insilico Medicine builds on their existing collaboration, which began in 2023, following the signing of an AI-based software licensing agreement. Insilico Medicine develops its AI technologies outside China, primarily in Canada and the Middle East, while carrying out early-stage preclinical drug development in China.

The partnership is expected to accelerate the identification of promising therapeutic candidates across multiple disease areas, leveraging Insilico Medicine's AI-enabled discovery capabilities. Eli Lilly plans to invest $3 billion in China over the next decade, expanding its manufacturing capacities and local supply chains in the country.

The shift towards AI in pharmaceutical research and development is gaining momentum, with companies relying on advanced modeling tools and automated laboratories to improve efficiency across their pipelines. This move also aligns with the US Food and Drug Administration's (FDA) efforts to reduce animal testing in the near future.